Genzyme received approval from the European Commission for the production of Myozyme (alglucosidase alfa) at the 4000 liter bioreactor scale at its manufacturing facility in Geel, Belgium. The product will be made commercially available immediately. Myozyme is the only approved treatment for Pompe disease, a progressively debilitating and often fatal inherited disorder. “This approval is important because it ensures that we can supply Myozyme to all patients in Europe who need treatment,” sai...